Kinase inhibitors and their uses

Details Kinase inhibitors and their uses Kinase inhibitors and their uses

2006-12-15

2009-10-13

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S266400, C514S234200, C514S218000, C514S252160, C514S252170, C514S252110, C514S260100, C514S265100, C514S258100, C514S264110, C514S263200, C514S263400, C514S263220, C514S263240, C514S262100, C544S291000, C544S277000, C544S105000, C544S280000, C544S118000, C544S117000, C544S253000, C544S279000, C544S262000, C544S285000, C544S278000, C540S575000

Reexamination Certificate

active

07601713

ABSTRACT:
The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity. The compounds of the present invention are according to structural formula (I):or a salt or N-oxide thereof, whereinB is selected from

REFERENCES:
patent: 7041824 (2006-05-01), Bordon-Pallier et al.
patent: 2005/0176707 (2005-08-01), Chen et al.
patent: 2006/0035891 (2006-02-01), Li et al.
patent: 2007/0135457 (2007-06-01), Beyer et al.
patent: WO9716452 (1997-05-01), None
patent: WO0049018 (2000-08-01), None
patent: WO 0109134 (2001-02-01), None
patent: WO 0132632 (2001-05-01), None
patent: WO 02102314 (2002-12-01), None
patent: WO 2004037823 (2004-05-01), None
patent: WO 2005016528 (2005-02-01), None
patent: WO 2005047524 (2005-05-01), None
patent: WO 2005049616 (2005-06-01), None
patent: WO 2005097135 (2005-10-01), None
patent: WO2005118544 (2005-12-01), None
patent: WO2006055528 (2006-05-01), None
patent: WO2006055561 (2006-05-01), None
Goldman, et al., N. England J. Med., 344, 14, Apr. 5, 2001.
Ekman, et al., Oncogene (2000) 19, 4151-58.
Xu, et al., J. Biol. Chem., 273, 50, Dec. 11, 1998. 33230-38.
Zhang, et al., J. Biol. Chem., vol. 279, No. 53, Dec. 31, 2004, pp. 55348-55354.
Lopes de Menezes, et al., Clin. Cancer Res. 2005:11 (14), Jul. 15, 2005, 5281-91.
Kawahara, et al., J. Clin. Onc., 2006 ASCO Annual Meeting Proceedings, Part I, vol. 24, No. 18S, Jun. 20, 2006, 13163.
Yoshida, et al., J. Neurochem., 2004, 90, 352-58.
Griesser , Chapter 8, The Importance of Solvates (pp. 211-230), in the text, Polymorphism: In the Pharmaceutical Industry, Hilfiker, 2006.
Brandlin, et al., J. Biol. Chem., vol. 277, No. 8, 2002, 6490-6496.
Wu, et al., Am. J. Pathol., 156, Jun. 6, 2000.
Rane, et al., Oncogene (2000) 19, 5662-5679.
Oshiro, et al., Clinical Cancer Research, vol. 7, 4262-4271, Dec. 2001.
Nakano, et al., FEBS Letters, 387 (1996) 75-77.
Kyttaris, et al., Clin Immunol. Sep. 2007; 124(3): 235-237.
Khan, et al., Journal of Allergy and Clinical Immunology, vol. 119, Issue 5, Mar. 6, 2007, p. 1277.
Brittain, Chapter V of Polymorphism in Pharmaceutical Solids, 1999, pp. 126-127.
Perreira, et al., “Reversine” and its 2-Substituted Adenine Derivatives as Potent and Selective A3 Adenosine Receptor Antagonists, J Med Chem, 2005, 48 (15), pp. 4910-4918.

Affiliated with

Also associated with

Rating

Kinase inhibitors and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Kinase inhibitors and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinase inhibitors and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4130684